Group items tagged

Elemental information and data relating to the clinical trials on fatty liver disease including an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe offers a perspective on the fatty liver disease clinical trial scenario. Disease clinical trials by their phase, trial status, prominence of the sponsors pertaining to the number of trials for the key drugs for treating fatty liver disease hints at the dynamics of a particular indication in a condensed manner in addition to the commercial landscape of the major universities, institutes, hospitals or companies.

One of the main drivers propelling the growth of the market for drugs used to treat patients with Parkinson's disease is the steadily growing aging population worldwide. This is because the number of patients suffering from Parkinson's disease is increasing owing to the rise in aging population both in the developing as well as developed nations. One of the major challenges to market growth is the weak pipeline landscape. Most products in the pipeline lack molecules that can potentially achieve blockbuster status in the near future.

According to diagnostic ultrasound imaging market forecasts, the global disease incidence is expected to rise and an early diagnosis of disease is the foundation for increasing survival rates. Diagnostic ultrasound imaging is the most widely used technique to achieve early detection and clinical assessment of adult and pediatric patients alike, making it a cornerstone of disease control. In the diagnostic ultrasound imaging market landscape GE Healthcare currently dominates the global diagnostic ultrasound market.

This report provides comprehensive information on the therapeutic development for Parkinson's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Dry eye syndrome (DES), or keratoconjunctivitis sicca, is a multifactorial disease of the eye caused by dryness, decreased tear production, or increased tear film evaporation. DES, which is often referred to simply as dry eye, is the most prevalent form of ocular discomfort and irritation. The most common symptoms of DES are ocular irritation and discomfort, foreign body sensation, fatigue, and visual disturbances, which interfere with daily activities. In the elderly population, it is the most common reason for seeking eye care, and this is expected to increase exponentially with an aging demographic.

This report includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Abdominal Obesity.

Interesting info. What other meds can be taken?

As far as I know, Xenical (Orlistat) promotes weight loss by decreasing the amount of dietary fat absorbed in your intestines. You can find out more about it on the Canada Drugs site https://www.canadadrugsdirect.com/. It has to be noted, that this medication should only be used under the supervision of a trained healthcare professional.